In breast cancer, SBFI26, an inhibitor of FABP5, induces ferroptosis by elevating levels of ferrous ions and lipid peroxidation, increasing the expression of ALOXE3, ALOX5, and ALOX15, thus driving ferroptosis in tumor cells (He et al., 2024). Here, ALOX5 is linked to neoplasm.